InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.46
(
1.25%
)
US TECH 100
17,426.40
(
2.05%
)
Dow Jones
38,679.67
(
1.19%
)
Brent Oil
82.82
(
-0.97%
)
Bitcoin
61,880.83
(
4.67%
)
Post# of 251700
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119559
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 11/16/2015 10:59:52 AM

Monday, November 16, 2015 10:59:52 AM

Post# of 251700
MRK reports phase-2 data for 3-DAA regimen including Grazoprevir (PI), MK-3682 (the nuke acquired from IDIX), and either Elbasvir or MK-8408 (NS5A):

http://finance.yahoo.com/news/merck-announces-presentation-results-two-133000564.html

All patients were treatment-naive and non-cirrhotic. The best-performing cohort was Grazoprevir + MK-8408 + (high-dose) MK-3682, which produced SVR12 rates of 91% in GT1 and GT3; and 94% in GT2. This is the combination being advanced to phase-2b.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up